Shanghai Henlius Biotech, Inc. engages in the research and development of biologic medicines with a focus on oncology, autoimmune diseases, and ophthalmic diseases. It offers HANLIKANG, a rituximab injection for treating non-hodgkin lymphoma, chronic lymphocytic leukemia, and rheumatoid arthritis; HANQUYOU, a trastuzumab injection to treat breast and metastatic breast and gastric cancer; HANDAYUAN, an adalimumab injection for the treatment of rheumatoid arthritis, ankylosing spondylitis, plaque psoriasis, and uveitis; HANBEITAI, a bevacizumab injection to treat metastatic colorectal cancer (mCRC) and recurrent non-small cell lung cancer; and HANSIZHUANG, a serplulimab injection for microsatellite instability-high solid tumors. The company also develops Serplulimab to treat squamous-cell carcinomas, gastric cancer, small cell lung cancer, hepatocellular carcinoma, metastatic colorectal cancer, solid tumors, SCCHN, sqNSCLC, hepatocellular carcinoma, and esophageal squamous cell carcinoma; HLX04-O, an anti-VEGF monoclonal antibody injection for wet age-related macular degeneration; HLX22 to treat breast and metastatic gastric cancer; HLX6018 to treat idiopathic pulmonary fibrosis; HLX07, HLX22, HLX208, HLX60, HLX42, HLX43, HLX53, and HLX51 to treat solid tumors; HLX11 to treat breast cancer; HLX05, a cetuximab injection for mCRC and SCCHN; and HLX14 to treat osteoporosis. In addition, it develops HLX26 for the treatment of solid tumor and lymphoma; HLX13 to treat melanoma, renal cell carcinoma, and mCRC; and HLX15 for multiple myeloma. The company operates in Mainland China, the Asia Pacific, North and South America, and Europe. The company was founded in 2010 and is headquartered in Shanghai, China. Address: Building B8, Shanghai, China, 200233